What stands behind the unusual deal of pharmaceutical giant Pfizer in the obesity market
Pfizer has enlisted Blackstone Life Sciences to finance the development of its obesity drug for up to $1.5 billion, an unusual deal for a giant company. Meanwhile, Alpha Tau reported positive results in a glioblastoma trial, and Google DeepMind launched a new model for predicting the impact of genetic mutations.
Pharmaceutical giant Pfizer announced the recruitment of an external party, Blackstone Life Sciences, to finance the development of its monthly injectable obesity treatment. Under the agreement, Blackstone will fund development costs of up to $1.5 billion in exchange for a share of future revenues. This is an unusual deal, as giant companies like Pfizer typically fund development themselves. Pfizer, with $14.3 billion in cash and long-term debt of about $60 billion from its acquisition of Seagen, faces a 'patent cliff.' The company plans ten clinical trials simultaneously for various obesity-related indications. Additionally, Alpha Tau reported positive results in a glioblastoma trial, with a median life expectancy of 6.9 months among 8 patients. The company hopes to reach 20 patients by the end of the first quarter of 2027 and receive marketing approval as early as late 2027 or early 2028. Google DeepMind launched AlphaGenome2, a model for predicting the impact of genetic variations on cells.
What stands behind the unusual deal of pharmaceutical giant Pfizer in the obesity market